GKOS

164.19

3.56% 5.64

Handel nachbörslich: 164.19

Glaukos Corp (GKOS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$158.55

Offen:

$158.31

24-Stunden-Volumen:

835.01K

Relative Volume:

1.03

Marktkapitalisierung:

$9.68B

Einnahmen:

$551.35M

Nettoeinkommen (Verlust:

$-189.33M

KGV:

-49.88

EPS:

-3.2916

Netto-Cashflow:

$-35.09M

1W Leistung:

+6.97%

1M Leistung:

-8.56%

6M Leistung:

+52.51%

1J Leistung:

+101.34%

1-Tages-Spanne:

$157.29

$165.65

1-Wochen-Bereich:

$151.01

$165.65

52-Wochen-Spanne:

$73.16

$191.62

Glaukos Corp Stock (GKOS) Company Profile

Firmenname

Glaukos Corp

Sektor

Healthcare (1062)

Branche

Medical Devices (138)

Telefon

949-367-9600

Adresse

1 GLAUKOS WAY, ALISO VIEJO, CA

Mitarbeiter

1,094

Twitter

@GlaukosCorp

Nächster Verdiensttermin

2026-11-04

Neueste SEC-Einreichungen

GKOS's Discussions on Twitter

Compare GKOS vs ABT, MDT, SYK, BSX, EW

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
GKOS Glaukos Corp	164.19	9.11B	551.35M	-189.33M	-35.09M	-3.2916
ABT Abbott Laboratories	98.83	175.27B	46.59B	5.41B	7.38B	3.0938
MDT Medtronic Plc	86.29	113.38B	36.36B	4.84B	5.43B	3.7261
SYK Stryker Corp	275.39	104.47B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	43.65	63.65B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	86.32	49.74B	6.30B	1.07B	1.09B	1.8406

Glaukos Corp Stock (GKOS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-07-06	Eingeleitet	H.C. Wainwright	Buy
2025-10-27	Hochstufung	Wells Fargo	Equal Weight → Overweight
2025-10-01	Eingeleitet	Goldman	Buy
2025-05-01	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-02-19	Hochstufung	Mizuho	Neutral → Outperform
2024-12-11	Hochstufung	Citigroup	Neutral → Buy
2024-12-06	Eingeleitet	UBS	Buy
2024-12-02	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2024-07-10	Herabstufung	Citigroup	Buy → Neutral
2024-05-06	Hochstufung	Jefferies	Hold → Buy
2023-12-21	Hochstufung	JP Morgan	Neutral → Overweight
2023-12-04	Eingeleitet	Morgan Stanley	Equal-Weight
2023-11-28	Eingeleitet	Truist	Buy
2023-11-08	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-06-07	Hochstufung	Piper Sandler	Neutral → Overweight
2022-12-22	Eingeleitet	Mizuho	Neutral
2022-12-19	Hochstufung	JP Morgan	Underweight → Neutral
2022-12-12	Hochstufung	Citigroup	Neutral → Buy
2022-10-14	Fortgesetzt	Stephens	Overweight
2022-10-04	Eingeleitet	Needham	Buy
2022-07-12	Hochstufung	Stifel	Hold → Buy
2022-02-03	Hochstufung	William Blair	Mkt Perform → Outperform
2022-01-19	Hochstufung	Wells Fargo	Underweight → Equal Weight
2022-01-18	Hochstufung	BTIG Research	Neutral → Buy
2021-11-03	Hochstufung	Stephens	Equal-Weight → Overweight
2021-07-26	Herabstufung	Stephens	Overweight → Equal-Weight
2021-07-20	Herabstufung	Wells Fargo	Equal Weight → Underweight
2021-07-14	Herabstufung	Oppenheimer	Outperform → Perform
2021-07-14	Herabstufung	William Blair	Outperform → Mkt Perform
2021-04-08	Hochstufung	Oppenheimer	Perform → Outperform
2021-01-29	Herabstufung	Piper Sandler	Overweight → Neutral
2020-12-16	Hochstufung	Citigroup	Sell → Neutral
2020-12-09	Eingeleitet	Oppenheimer	Perform
2020-11-17	Hochstufung	Wells Fargo	Underweight → Equal Weight
2020-10-08	Herabstufung	JP Morgan	Neutral → Underweight
2020-06-15	Eingeleitet	Jefferies	Hold
2020-03-05	Eingeleitet	Citigroup	Sell
2020-02-28	Herabstufung	JP Morgan	Overweight → Neutral
2020-01-06	Hochstufung	Berenberg	Hold → Buy
2019-12-12	Herabstufung	Wells Fargo	Outperform → Underperform
2019-09-30	Herabstufung	BofA/Merrill	Buy → Underperform
2019-03-08	Eingeleitet	BTIG Research	Neutral
2018-08-30	Eingeleitet	Berenberg	Hold
2018-08-29	Hochstufung	JP Morgan	Neutral → Overweight
2018-08-03	Bestätigt	Stifel	Hold
2018-06-21	Herabstufung	JP Morgan	Overweight → Neutral
2018-04-13	Herabstufung	Stifel	Buy → Hold
2018-03-01	Bestätigt	Cantor Fitzgerald	Buy
2017-03-02	Bestätigt	Cantor Fitzgerald	Overweight
2017-01-06	Hochstufung	Stifel	Hold → Buy
2016-10-27	Eingeleitet	Wells Fargo	Outperform

Alle ansehen

Glaukos Corp Aktie (GKOS) Neueste Nachrichten

Sep 26, 2026

Form 144 GLAUKOS Corp For: 26 September By Investing.com - Investing.com Nigeria

Sep 26, 2026

Sep 25, 2026

A Glaukos (NYSE: GKOS) officer proposes selling 1,615 shares on September 25. - Stock Titan

Sep 25, 2026

Sep 24, 2026

Presbyopia Market Expected to Transform with Next-Generation Therapies and Strong Growth Through 2036 – DelveInsight | AbbVie, Orasis Pharma, Eyenovia, Glaukos Corp., Ocuphire Pharma, Novartis - Barchart.com

Sep 24, 2026

Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now - Yahoo Finance

Sep 24, 2026

Glaukos Corporation (GKOS) Stock Forecasts - Yahoo! Finance Canada

Sep 24, 2026

Glaukos Partners with NBA Champion Stephen Curry to Launch “Could - The National Law Review

Sep 24, 2026

Zacks Investment Research - globes.co.il

Sep 24, 2026

Sep 23, 2026

A Look at Glaukos Corp (GKOS) After 4.0% Decline -- GF Value $15 - gurufocus.com

Sep 23, 2026

Jefferies Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $210 - moomoo.com

Sep 23, 2026

$1000 Invested In Glaukos 10 Years Ago Would Be Worth This Much Today - Benzinga

Sep 23, 2026

Stephen Curry is sharing his story to help families spot signs of a sight-threatening eye disease. - stocktitan.net

Sep 23, 2026

Glaukos stock gains institutional support as Bank of America builds position - AD HOC NEWS

Sep 20, 2026

Sep 18, 2026

Glaukos chief development officer Tomas Navratil sells $243k in shares - Investing.com

Sep 18, 2026

Sep 16, 2026